Alpha Tau Medical Ltd.

NasdaqCM DRTS

Alpha Tau Medical Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -29.02%

Alpha Tau Medical Ltd. Return on Capital Employed (ROCE) is -29.02% for the year ending December 31, 2023, a 0.34% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Alpha Tau Medical Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -29.12%.
Alpha Tau Medical Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -18.16%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqCM: DRTS

Alpha Tau Medical Ltd.

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street
Employees	121
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends

Past 5 years